GlassScriptPhysician profile
Joey A Tryon
NPI 1073729174
$1,809.58
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $931 · 2020: $229 · 2021: $28.10 · 2022: $184 · 2023: $363 · 2024: $74.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $437.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $317.24 | 2019-2023 | Vraylar, Qulipta |
| Pfizer INC. | $274.76 | 2019-2023 | |
| Novo Nordisk INC | $246.29 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $154.54 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $103.62 | 2023 | Ingrezza |
| Merck Sharp & Dohme LLC | $82.78 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $79.55 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.40 | 2020-2023 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.72 | 2019-2020 | |
| Lilly USA, LLC | $43.99 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.49 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $37.07 | 2019 | |
| Amarin Pharma, INC. | $36.81 | 2020 | |
| Janssen Pharmaceuticals, INC | $30.56 | 2019 | |
| Antares Pharma, INC. | $23.97 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $23.08 | 2023 | Prolia, Evenity |
| Medtronic Vascular, INC. | $20.85 | 2020 | |
| Melinta Therapeutics, LLC | $19.57 | 2019 | |
| Valeritas, INC. | $18.56 | 2019 | |
| Scilex Pharmaceuticals INC. | $17.95 | 2019 | |
| Sanofi Pasteur INC. | $17.25 | 2023 | |
| Mylan Specialty L.P. | $16.95 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.21 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.07 | 2019 | |
| Avion Pharmaceuticals | $12.95 | 2019 | |
| Allergan, INC. | $12.80 | 2019 | |
| Alkermes, INC. | $12.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joey Tryon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.